# B Cell/T Cell Interactions in Brucellosis

> **NIH NIH R01** · UNIVERSITY OF MISSOURI-COLUMBIA · 2022 · $50,093

## Abstract

Project Summary/Abstract
 In humans, Brucella spp. can cause a lifelong, debilitating disease, with relapses of undulating fever and
other complications even with antibiotic treatment. No vaccines are currently licensed to prevent human
brucellosis. In this focused Supplement, we will employ the BSL3 cell sorting capability of the University of
Missouri Regional Biocontainment Laboratory (MURBL) along with RNA-seq to perform detailed transcriptional
analyses of B and T cells in our model of vaccine-mediated immunity to Brucella. Our findings from this
Supplement will complement the results from our parental proposal and provide us additional information which
will enhance our understanding of how B cell antigen presentation inhibits vaccine-mediated immunity against
Brucella, which in turn could improve the rational design of vaccines for brucellosis.

## Key facts

- **NIH application ID:** 10630491
- **Project number:** 3R01AI150797-02S1
- **Recipient organization:** UNIVERSITY OF MISSOURI-COLUMBIA
- **Principal Investigator:** Jerod Skyberg
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $50,093
- **Award type:** 3
- **Project period:** 2020-11-18 → 2023-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10630491

## Citation

> US National Institutes of Health, RePORTER application 10630491, B Cell/T Cell Interactions in Brucellosis (3R01AI150797-02S1). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/10630491. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*